ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

NVCN Neovasc Inc

30.03
0.00 (0.00%)
16 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Neovasc Inc NASDAQ:NVCN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 30.03 27.70 30.00 0 01:00:00

Neovasc Announces Second Quarter 2018 Financial Results Conference Call and Webcast

02/08/2018 12:30pm

PR Newswire (Canada)


Neovasc (NASDAQ:NVCN)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Neovasc Charts.

NASDAQ, TSX: NVCN

VANCOUVER, Aug. 2, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that it will report financial results for the quarter and six months ended June 30, 2018 and host a conference call and webcast at 4:30pm Eastern Time on Wednesday, August 8, 2018.

Conference Call & Webcast


Wednesday, August 8th @ 4:30pm Eastern Time


Domestic:

888-254-3590

International:  

323-994-2093

Passcode:  

9226007

Webcast:

http://public.viavid.com/index.php?id=130206



Replays available through August 22nd:


Domestic:

844-512-2921

International:

412-317-6671

Conference ID:

9226007

                                                              

About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc Reducer™ (the "Reducer"), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara™ (the "Tiara"), for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States , Canada and Europe . For more information, visit: www.neovasc.com.

SOURCE Neovasc Inc.

Copyright 2018 Canada NewsWire

1 Year Neovasc Chart

1 Year Neovasc Chart

1 Month Neovasc Chart

1 Month Neovasc Chart

Your Recent History

Delayed Upgrade Clock